All‐cause mortality · Adults with COPD
Statins showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early all‐cause mortality (≤ 3 months) Reported at: 28 days; 60 days; and during hospital stay · adults with acute respiratory distress syndrome
Statins showed no clear difference in early all‐cause mortality (≤ 3 months) Reported at: 60 days; and… compared with control (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with improving outcomes during and after noncardiac vascular surgery.
Perioperative statins showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · adults with chronic kidney disease
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · adults with chronic kidney disease
The intervention showed no clear difference in all‐cause mortality (moderate certainty).
1 finding from 1 review